Coya Therapeutics, Inc. Investing Cash Flow
Coya Therapeutics, Inc. (COYA) reported Investing Cash Flow of -$886.66 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivities · last filed 2026-08-11
- Coya Therapeutics, Inc. net cash provided by (used in) investing activities for the quarter ending 2026-06-30 was -$1.66K.
- Coya Therapeutics, Inc. net cash provided by (used in) investing activities for the quarter ending 2026-03-31 was -$885.00K.
- Coya Therapeutics, Inc. net cash provided by (used in) investing activities for the quarter ending 2025-12-31 was -$648.61K.
- Coya Therapeutics, Inc. net cash provided by (used in) investing activities for the quarter ending 2024-12-31 was $0.00.
- Coya Therapeutics, Inc. net cash provided by (used in) investing activities for fiscal 2025 was -$1.16M.
- Coya Therapeutics, Inc. net cash provided by (used in) investing activities for fiscal 2024 was -$25.00K.
- Coya Therapeutics, Inc. net cash provided by (used in) investing activities for fiscal 2023 was -$543.19K.
- Coya Therapeutics, Inc. net cash provided by (used in) investing activities for fiscal 2022 was -$525.00K.
| Period end | Net Cash Provided by (Used in) Investing Activities 3 month | Net Cash Provided by (Used in) Investing Activities 6 month | Net Cash Provided by (Used in) Investing Activities 9 month | Net Cash Provided by (Used in) Investing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$1.66K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$886.66K 10-Q · filed 2026-08-11 | -$1.54M derived: sum of 3 quarters · filed 2026-08-11 | |
| 2026-03-31 | -$885.00K 10-Q · filed 2026-05-12 | -$1.53M derived: sum of 2 quarters · filed 2026-05-12 | ||
| 2025-12-31 | -$648.61K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | -$1.16M 10-K · filed 2026-03-16 | ||
| 2025-09-30 | -$516.00K 10-Q · filed 2025-11-12 | |||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $0.00 derived: sum of 2 quarters · filed 2026-03-16 | $0.00 derived: sum of 3 quarters · filed 2026-03-16 | -$25.00K 10-K · filed 2026-03-16 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $0.00 derived: sum of 2 quarters · filed 2025-11-12 | -$25.00K 10-Q · filed 2025-11-12 | -$218.19K derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | -$25.00K 10-Q · filed 2025-08-12 | -$218.19K derived: sum of 3 quarters · filed 2025-08-12 | -$218.19K derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | -$25.00K 10-Q · filed 2025-05-13 | -$218.19K derived: sum of 2 quarters · filed 2025-05-13 | -$218.19K derived: sum of 3 quarters · filed 2025-05-13 | |
| 2023-12-31 | -$193.19K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | -$193.19K derived: sum of 2 quarters · filed 2025-03-18 | -$543.19K 10-K · filed 2025-03-18 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | -$350.00K 10-Q · filed 2024-11-06 | ||
| 2023-06-30 | -$350.00K 10-Q · filed 2024-08-12 | |||
| 2022-12-31 | -$390.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | -$525.00K 10-K · filed 2024-03-19 | ||
| 2022-09-30 | -$135.00K 10-Q · filed 2023-11-08 | |||
| 2021-12-31 | -$136.80K 10-K · filed 2023-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |